E. coli Genome-wide CRISPRi under multiple chemical treatments
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB33267 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR12040415.fastq.gz | Fastqsanger.gz | |||
| ERR12040416.fastq.gz | Fastqsanger.gz | |||
| ERR12040417.fastq.gz | Fastqsanger.gz | |||
| ERR12040418.fastq.gz | Fastqsanger.gz | |||
| ERR12040419.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 75 |
Similar Datasets
Project description:Pre-existing cell states predict resistance to multiple treatments
| PRJNA1171004 | ENA
Project description:we performed lentiviral CRISPR interference (CRISPRi) by recruiting dCas9 fused with the KRAB domain to the CSMD1 enhancer (fam3) in the neuronal precursor cell line – Lund human mesencephalic (LUHMES). Given that the expression of CSMD1 was not detectable in LUHMES cells we differentiated these cells into neurons. Differentiated neurons with CRISPRi of CSMD1 enhancer showed significantly higher expression of CSMD1 than control.
2022-06-30 | E-MTAB-8027 | biostudies-arrayexpress
Project description:We develop a system for bidirectional epigenetic editing (CRISPRai), in which orthogonal activating (CRISPRa) and repressive (CRISPRi) perturbations are applied simultaneously to multiple loci the same cell. We perform ATAC-seq on CRISPRi perturbed Jurkat T cells to investigate chromatin accessibility changes upon perturbation of individual regulatory elements.
2024-03-16 | GSE261695 | GEO
Project description:Background: The CRISPR/Cas9 toolbox has recently been expanded to include approaches for modulating gene expression. To successfully build on this work, and apply it for answering biological questions, it is important to establish it in a broad range of circumstances. Genome-scale CRISPR interference (CRISPRi) has been used in human cells lines, however the rules for designing effective guide RNAs (gRNAs) in different organisms are not well known. We sought to determine rules that determine gRNA effectiveness at transcriptional repression in Saccharomyces cerevisiae. Results: We created an inducible single plasmid CRISPRi system for gene repression in yeast, and used it to analyze fitness effects of gRNAs under 18 small molecule treatments. Our approach correctly identified previously-described chemical-genetic interactions, as well as a new mechanism of suppressing fluconazole toxicity by repression of the ERG25 gene. Assessment of multiple target loci across treatments allowed us to determine generalizable features associated with gRNA efficacy. Guides that target regions with low nucleosome occupancy and high chromatin accessibility were clearly more effective. We also found the best region to target gRNAs was between the transcription start site (TSS) and 200bp upstream of the TSS. Finally, unlike nuclease-proficient Cas9 in human cells, point mutations were tolerated equally well by truncated (18 nt specificity sequence) and full length (20 nt) gRNAs, however, 18 nt gRNAs were generally less potent than full length gRNAs. Conclusions: Our results establish a powerful functional genomics screening method, provide rules for designing effective gRNAs for gene repression, and show that 18 nt and 20 nt gRNAs exhibit similar tolerance to mismatches in the target sequence. These findings will enable effective library design and genome-wide screening in many genetic backgrounds. An expression construct was created for inducible CRISPRi in yeast. Key features include ORFs expressing dCas9-Mxi1 and the tetracycline repressor (TetR), as well as a tetracycline inducible gRNA locus containing the RPR1 promoter with a TetO site, a NotI site for cloning new gRNA specificity sequences, and the constant part of the gRNA. When yeast containing this plasmid are grown in the absence of anhydrotetracycline (ATc) TetR binds the gRNA promoter and prevents PolIII from binding and transcribing the gRNA. This in turn prevents dCas9-Mxi1 from binding the target site. In the presence of ATc, TetR dissociates and gRNA is expressed, allowing dCas9-Mxi1 to bind its target locus, and repress gene expression. gRNA libraries were cloned into this construct and transformed into yeast to create pools. Experiments were conducted in which yeast pools were grown in inducing (+ATc) and non-inducing conditions (-ATc) in the presence of different drugs. After multiple generations of growth in these conditions, yeast plasmids were minipreped and the gRNA locus was PCRed and sequenced via MiSeq. Counts of each gRNA were compared in different conditions.
2016-01-18 | E-GEOD-71490 | biostudies-arrayexpress
Project description:Assess the on- and off-target effects of dox-inducible CRISPR/Cas9 and CRISPRi constructs in a human iPS cell line. Transcript quantification of 3 cell lines, each plus or minus doxycycline and with or without specific single guide RNAs (sgRNAs), with 2 biological replicates each.
2016-01-19 | E-GEOD-76980 | biostudies-arrayexpress
Project description:Pre-existing differences between individual cancer cells can predict which cells will become resistant upon the application of treatment. This understanding has been furthered by novel methods in DNA barcoding that allow tracking of clones and their cell states during treatment. However, previous studies using these techniques have been limited in their scope, focusing on how single cell-states lead to resistance to a single treatment. In this study, we performed multi-treatment, high-throughput clonal tracking and single-cell RNA-sequencing to trace rare clones through the development of resistance to many different treatments in parallel with the goal of identifying cell states associated with multi-treatment resistance. We found that clones that will go on to develop resistance to one treatment had an increased chance of separately developing resistance to other treatments with diverse mechanisms of action. Additionally, we identified high CD44 expression in treatment-naive cells as a predictor of future resistance to multiple different treatments. Furthermore, for cells within the same treatment condition, we found that differences in gene expression states prior to treatment can lead cells to follow divergent paths towards their ultimate resistance fate. This work provides a framework for extracting targetable gene expression states from complex resistance dynamics across multiple treatments to eliminate multi-treatment resistance.
2024-10-14 | GSE279162 | GEO
Project description:To delineate cellular pathways underlying cell growth in the absence of sphingolipid syntehsis, we performed a genome-wide CRISPRi screen to identify genetic modifiers of myriocin sensitivity in human K562 cells.
2020-07-09 | GSE154045 | GEO
Project description:Genome-wide CRISPRi screen for myriocin sensitivity
| PRJNA644921 | ENA
Project description:Genome-wide CRISPRi screening of Eubacterium limosum
| PRJEB49804 | ENA
Project description:In this study, we developed a workflow to systematically and selectively induce increases in metabolites by knocking down enzymes with CRISPR interference (CRISPRi). Therefore, we created a sorted CRISPRi library targeting all 1,515 metabolic genes in the most recent genome-scale metabolic model of E. coli (iML151515). In a first step, we screened the metabolome of the CRISPRi library with a fast flow-injection mass spectrometry, which revealed strong and specific accumulation of 36% of the predicted metabolites in the iML1515 model. The accumulating metabolites were unique to certain knockdowns, especially those metabolites associated with the CRISPRi targeted-pathway.
2024-08-07 | MSV000095534 | MassIVE